Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.

2019-01

Miller, Aaron E

Xu, Xianhao

Macdonell, Richard A L

Vucic, Steve

Truffinet, Philippe

Benamor, Myriam

Thangavelu, Karthinathan

Freedman, Mark S

Clinical trial

Disease-modifying therapy

Multiple sclerosis

Phase 3

Subgroup analysis

Teriflunomide

Journal Article

10.1016/j.jocn.2018.09.012

In the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS.

link

Journal of Clinical Neuroscience 2019; 59: 229-231

Journal of Clinical Neuroscience